MET and dementia: Further supporting this notion, two ongoing phase 2 trials in patients with mild-to-moderate AD dementia (NCT04488419) and Parkinson’s disease (PD) dementia or dementia with Lewy bodies (NCT04831281) are testing a drug targeting HGF and MET.